SCHEMBL5563769

SCHEMBL5563769

COC(=O)c1ccccc1CS(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
RORC P51449 2/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 1/20 0.48
CYP3A4 P08684 3/20 0.47
CYP2C19 P33261 3/20 0.47
RECQL P46063 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2D6 P10635 1/20 0.47
LMNA P02545 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP13 P45452 1/20 0.46
KDM4E B2RXH2 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31478923 0.85 POLB (0.59) POLBMEN1GAAKMT2ACYP3A4
SCHEMBL10927262 0.84 CFTR (0.48) POLBRORCMEN1GAAKMT2A
SCHEMBL4912518 0.82 ALDH1A1 (0.53) POLBMEN1KMT2ARECQLLMNA
SCHEMBL12812255 0.78 KDM4E (0.52) MEN1KMT2ACYP3A4CYP2C19MRGPRX4
SCHEMBL7569668 0.77 KMT2A (0.76) RORCMEN1GAAKMT2ALMNA
SCHEMBL29038826 0.76 MAPT (0.61) MEN1GAAKMT2ARECQLMRGPRX4
SCHEMBL5565855 0.75 PPARG (0.51) POLBGAAMRGPRX4KDM4EALDH1A1
SCHEMBL7363401 0.74 ALDH1A1 (0.57) POLBKMT2ALMNACA1CA2
SCHEMBL28104379 0.74 KAT6A (0.41) POLBGAAKMT2AMRGPRX4LMNA
SCHEMBL28835149 0.72 MAPT (0.42) MEN1KMT2ACYP3A4CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070004784-A1 Sulfonamides as potassium channel blockers ICAGEN, INC. (US) 2007-01-04 US disclosed
US-7119112-B2 Sulfonamides as potassium channel blockers ICAGEN, INC. (US) 2006-10-10 US disclosed
EP-1534259-A4 SULFONAMIDES AS POTASSIUM CHANNEL BLOCKERS ICAGEN INC (US) 2006-10-04 EP disclosed
US-20060094721-A9 Sulfonamides as potassium channel blockers ICAGEN, INC. (US) 2006-05-04 US disclosed
EP-1534259-A2 SULFONAMIDES AS POTASSIUM CHANNEL BLOCKERS Icagen, Inc. (US) 2005-06-01 EP disclosed
US-20040106613-A1 Sulfonamides as potassium channel blockers ICAGEN, INC. 2004-06-03 US disclosed
WO-2004016221-A2 SULFONAMIDES AS POTASSIUM CHANNEL BLOCKERS ICAGEN, INC (US) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094721-A9 Sulfonamides as potassium channel blockers KCNJ2, KCNJ1, KCNJ11 POLB 2287/4885RORC 4684/4885MEN1 2417/4885
US-20040106613-A1 Sulfonamides as potassium channel blockers KCNJ2, KCNJ1, KCNJ11 POLB 2287/4885RORC 4684/4885MEN1 2417/4885
US-20070004784-A1 Sulfonamides as potassium channel blockers KCNJ2, KCNJ1, KCNJ11 POLB 2287/4885RORC 4684/4885MEN1 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.